Last reviewed · How we verify
Performance
At a glance
| Generic name | Performance |
|---|---|
| Sponsor | VA New York Harbor Healthcare System |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. (NA)
- Creation of a Pediatric Reference Database for the Kerpape-Rennes-EMG-Based Gait Index (NA)
- Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.
- A Post-market-clinical Follow-up Investigation of Safety and Performance by Decoria® Intense Strong (NA)
- Impact of Anatomy-Based Cochlear Implant Programming on Early Performance (NA)
- Predicting Future Errors During Skill Performance
- Establishing of the Inter-rater Reliability and Variability of Selected Standardized Tests Performed in Czech Language
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Performance CI brief — competitive landscape report
- Performance updates RSS · CI watch RSS
- VA New York Harbor Healthcare System portfolio CI